BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18570731)

  • 1. [Expression of peroxisome proliferator-activated receptor-gamma in human pituitary adenomas and its correlation to tumor invasiveness].
    Huang CX; Hou YH; Zhao JN; Wang YT; Li JJ; Wen L
    Ai Zheng; 2008 Jun; 27(6):590-4. PubMed ID: 18570731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
    Emery MN; Leontiou C; Bonner SE; Merulli C; Nanzer AM; Musat M; Galloway M; Powell M; Nikookam K; Korbonits M; Grossman AB
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):389-95. PubMed ID: 16918962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary.
    Occhi G; Albiger N; Berlucchi S; Gardiman M; Scanarini M; Scienza R; Fassina A; Mantero F; Scaroni C
    J Neuroendocrinol; 2007 Jul; 19(7):552-9. PubMed ID: 17561883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Distribution and expression of peroxisome proliferator activated receptor gamma in human pituitary adenomas].
    Ma Y; Xia XW; Su CB; Kong YG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):375-7. PubMed ID: 16900637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
    Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
    Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of pituitary tumor transforming gene, endostatin, and basic fibroblast growth factor mRNAs in invasive pituitary adenomas].
    Chen L; Liu YS; Wang LS; Yin HG; Hou QT; Liu ZX; Chen LH; Ling F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):651-3, 666. PubMed ID: 16114549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of MMPPs and TIMP and invasiveness in pituitary adenomas].
    Wang J; Liu YS
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):647-50. PubMed ID: 16114548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas.
    Chen L; Liu Y; Hou Y; Kato Y; Sano H; Kanno T
    Neurosci Lett; 2007 Apr; 417(1):30-5. PubMed ID: 17398005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
    Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
    J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.
    Kristiansen G; Jacob J; Buckendahl AC; Grützmann R; Alldinger I; Sipos B; Klöppel G; Bahra M; Langrehr JM; Neuhaus P; Dietel M; Pilarsky C
    Clin Cancer Res; 2006 Nov; 12(21):6444-51. PubMed ID: 17085658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases.
    He Q; Chen J; Lin HL; Hu PJ; Chen MH
    Chin Med J (Engl); 2007 Sep; 120(17):1498-504. PubMed ID: 17908458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
    Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
    Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of pituitary homeo box 1 (Ptx1) in human non-neoplastic pituitaries and pituitary adenomas.
    Tahara S; Kurotani R; Sanno N; Takumi I; Yoshimura S; Osamura RY; Teramoto A
    Mod Pathol; 2000 Oct; 13(10):1097-108. PubMed ID: 11048804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.
    Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B
    Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
    He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
    Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary specific transcription factor messenger ribonucleic expression in adenomatous and nontumorous human pituitary tissues.
    Lloyd RV; Jin L; Chandler WF; Horvath E; Stefaneanu L; Kovacs K
    Lab Invest; 1993 Nov; 69(5):570-5. PubMed ID: 8246449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
    Saeger W; Lüdecke B; Lüdecke DK
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary study of p16 gene expression in pituitary adenomas].
    Yu WH; Hui GZ; Wang Q; Wu SR
    Ai Zheng; 2003 Feb; 22(2):198-201. PubMed ID: 12600300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
    Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
    Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
    Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
    Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.